A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524894-17-00

Enrollment

Registered

2026-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration (NVAMD)

Mean change in best-corrected visual acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS]) letter score from baseline to Year 1

DRUGAFLIBERCEPT

Sex/Gender

All

Age

18 Years to No maximum

Measure	Time frame
Mean change in best-corrected visual acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS]) letter score from baseline to Year 1	—

None listed

Source: EU CTIS · Data processed: Jun 6, 2026